CARM1: an epigenetic brake on cDC1-mediated antitumor immunity
Trends in Immunology · 2026
DOI: 10.1016/j.it.2026.08.002 ↗Kurz gefasst
Leserbrief in der Zeitschrift Trends in Immunology, 2026. Verfasst von Congliang Chen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Center for Immunotherapy, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical C…. Hauptthemen laut MEDLINE: Dendritic Cells, Epigenesis, Genetic, Neoplasms, Protein-Arginine N-Methyltransferases. Die Arbeit nennt 8 Literaturangaben. Gefördert von: Chinese Academy of Medical Sciences, National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Center for Immunotherapy, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China.
- Department of Immunology, Center for Immunotherapy, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China. Electronic address: caoxt@immunol.org.
Förderung
- Chinese Academy of Medical Sciences
- National Natural Science Foundation of China
Zitieren
APA
Chen, C., & Cao, X. (2026). CARM1: an epigenetic brake on cDC1-mediated antitumor immunity. Trends in Immunology. https://doi.org/10.1016/j.it.2026.08.002
Vancouver
Chen C, Cao X. CARM1: an epigenetic brake on cDC1-mediated antitumor immunity. Trends in Immunology. 2026. doi:10.1016/j.it.2026.08.002
BibTeX
@article{Chen2026,
author = {Chen, Congliang and Cao, Xuetao},
title = {CARM1: an epigenetic brake on cDC1-mediated antitumor immunity},
journal = {Trends in Immunology},
year = {2026},
doi = {10.1016/j.it.2026.08.002}
}
EUVIMED